← All trials
NCT02705534
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Sep 1, 2017
- Completion date
- Oct 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Isfahan UniversityLead sponsor
- Isfahan UniversityStudy chair
- Bakhtar Bioshimi CoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.